Physician

Eiran Zev Gorodeski, M.D., M.P.H.

According to 2025 Medicare claims, Eiran Gorodeski, M.D., M.P.H. (NPI: 1396729943) practices advanced heart failure and transplant cardiology in the Cleveland, OH market, with the plurality of this provider's patient population coming from Cuyahoga, OH. This provider's primary affiliated billing organization is UNIVERSITY HOSPITALS MEDICAL GROUP INC (NPI: 1669499414; TIN: 204881619) and primary practice location at 44122-4478. Gorodeski is affiliated with the Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under the REACH model.

Gorodeski's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 195 traditional Medicare patients, billed 512 HCPCS/CPT codes, and received $47,608 in Medicare payments. The top billing code was 99291 (Critical care, first 30-74 minutes). Part D data shows 3,401 prescription claims across 331 beneficiaries totaling $7,316,840 in drug costs, led by Vyndamax (Tafamidis). 2023 DME data shows 12 claims. Open Payments data shows 5 records totaling $413. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $32,663 and ending at $47,608. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $40,167 to $7,316,840. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	207	447	$32,663
2016	273	553	$41,819
2017	323	759	$56,340
2018	379	784	$58,938
2019	287	577	$43,821
2020	159	379	$28,933
2021	160	400	$42,614
2022	153	343	$34,703
2023	184	430	$45,412
2024	195	512	$47,608

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	128	845	$40,167
2016	161	1,056	$63,272
2017	250	1,757	$206,782
2018	289	2,256	$392,189
2019	302	2,112	$488,817
2020	239	1,721	$1,992,013
2021	181	2,096	$3,330,284
2022	248	2,871	$3,960,026
2023	305	3,055	$4,406,075
2024	331	3,401	$7,316,840

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	46	$2,168
2016	N/R	N/R	N/R
2017	N/R	36	$3,315
2018	N/R	12	$1,817
2019	N/R	N/R	N/R
2020	N/R	15	$557
2021	N/R	54	$1,500
2022	N/R	26	$610
2023	N/R	12	$866
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99291	Critical care, first 30-74 minutes	25	70	$162
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	72	103	$122
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	31	54	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	71	80	$78
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	37	42	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	228	7,200	$5,316,566
Entresto	Sacubitril/Valsartan	444	23,011	$504,591
Vyndaqel	Tafamidis Meglumine	22	660	$482,388
Farxiga	Dapagliflozin Propanediol	337	17,557	$318,608
Camzyos	Mavacamten	34	1,020	$277,379

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$413	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Eiran Zev Gorodeski, M.D., M.P.H.?

Tedicare shows public-source Medicare data for Eiran Zev Gorodeski, M.D., M.P.H. (NPI 1396729943), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Eiran Zev Gorodeski, M.D., M.P.H. have ACO affiliation data?

Eiran Zev Gorodeski, M.D., M.P.H. is shown with ACO affiliation data for Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Eiran Zev Gorodeski, M.D., M.P.H.?

Eiran Zev Gorodeski, M.D., M.P.H. is linked to UNIVERSITY HOSPITALS MEDICAL GROUP INC (billing NPI 1669499414) in the available physician profile data.

Does Eiran Zev Gorodeski, M.D., M.P.H. have Open Payments data?

Eiran Zev Gorodeski, M.D., M.P.H. has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.